{"success":true,"data":{"pressRelease":{"id":"30113","rtpr_id":"nBwbJF0dwa","ticker":"ALSMA","exchange":"Euronext Paris","all_tickers":["ALSMA"],"title":"SMAIO Expands Its North American Scientific Advisory Board With a New Renowned Surgeon","author":"Business Wire","published_at":"2026-05-11T16:40:00.174Z","article_body":"SMAIO Expands Its North American Scientific Advisory Board With a New Renowned\nSurgeon\n\n\n * Appointment of Dr. Jeffrey M. Hills, an orthopedic surgeon specializing in\ncomplex spinal conditions\n\n * SMAIO’s Scientific Advisory Board, now comprised of five members, is a key\nasset in the company’s expansion in the United States\n\nRegulatory News:\n\nSMAIO (Software, Machines and Adaptative Implants in Orthopaedics – Euronext\nGrowth Paris, ISIN: FR0014005I80 / Ticker: ALSMA), a French-American company\nspecialized in complex spine surgery and offering an integrated pre-, intra-\nand postoperative solution based on 3D planning software, announces the\nappointment of Dr. Jeffrey M. Hills, an orthopedic surgeon specializing in\ncomplex spinal surgery and Assistant Professor (Clinical) at UT Health San\nAntonio (Texas), to its North American Scientific Advisory Board.\n\nDr. Jeffrey M. Hills is a recognized specialist in the field of complex spinal\nconditions in adults and children. After graduating from the University of\nKansas School of Medicine, he completed his residency in orthopedic surgery at\nVanderbilt Medical Center in Nashville, Tennessee. He then completed a\nfellowship in spinal surgery at Washington University School of Medicine /\nBarnes-Jewish Hospital in St. Louis, Missouri, where he specialized in\npediatric and adult spinal deformities as well as complex reconstructive\nsurgeries.\n\nHis appointment to the SMAIO Scientific Advisory Board is part of the\ncompany’s strategy to build a network of leading experts in the United\nStates, the world’s largest market for spinal surgery. This board\ncontributes in particular to guiding technological developments, the clinical\nvalidation of solutions, and the organization of collaborative initiatives and\nexchange programs among spinal experts, such as the “Sagittal Alignment\nThink Tanks.”\n\nDr. Jeffrey M. Hills, an orthopedic surgeon, stated: “Joining SMAIO’s\nscientific advisory board represents an opportunity to contribute to the\ndevelopment of innovative solutions in spinal surgery. The integration of\nclinical data and predictive analytics tools is essential to improving patient\noutcomes. The approach developed by SMAIO, particularly through its open\nplatform, is fully in line with this trend.”\n\nPhilippe ROUSSOULY, Chairman and CEO of SMAIO, concluded: “We are very\npleased to welcome Dr. Hills to our North American Scientific Advisory Board.\nHis expertise in complex spinal surgery and his interest in data-driven\napproaches are significant assets that will support our growth in the United\nStates. This appointment underscores our commitment to surrounding ourselves\nwith the best specialists to strengthen our position in this strategic\nmarket.”\n\nDr. Jeffrey M. Hills thus becomes the fifth member of SMAIO’s North American\nScientific Advisory Board, joining Dr. Donald J. Blaskiewicz (neurosurgeon at\nSt. Luke’s Clinic in Boise, Idaho), Dr. Brian Neuman (orthopedic surgeon)\nand Dr. Camilo Molina (neurosurgeon), both practicing at Washington University\nSchool of Medicine in St. Louis, Missouri, and Dr. Tenner Guillaume\n(orthopedic surgeon at Gillette Children’s Hospital in St. Paul, Minnesota).\n\nThe terms of remuneration of Dr. Jeffrey M. Hills as a member of the\nScientific Advisory Board, mainly in the form of warrants issued to its\nbenefit, are detailed in the appendix to this press release.\n\nAbout SMAIO\n\nA precursor in the use of clinical data and imaging of the spine, SMAIO\ndesigns global solutions for spine surgery specialists. The Company has\nrecognized expertise thanks to its big data database, which has become a\nglobal reference with more than 100,000 patient cases documented. SMAIO offers\nspine surgeons a comprehensive platform, i-Kontrol, incorporating planning,\nimplantable devices and related services, enabling them to treat spinal\npathologies in a safe, effective and lasting way. The open platform deployed\nby the Company in the United States, KEOPS-4ME, is designed to offer a\npersonalized and data-driven approach for complex spine surgeries, enabling\nSMAIO to enter into commercial partnerships with major US surgical companies\nand to provide their surgeon customers with patient-specific implants. Based\nin Dallas (United States) and Lyon (France), SMAIO benefits from the skill and\nexpertise of more than 40 highly specialized employees.\n\nFor further information, please visit: www.smaio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.smaio.com&esheet=54533537&newsitemid=20260511764184&lan=en-US&anchor=www.smaio.com&index=1&md5=0e66aebbbf57f85c095f6544388c0f52)\n\nListing market: Euronext Growth Paris\n\nISIN : FR0014005I80\n\nTicker: ALSMA\n\nDisclaimer\n\nThis press release contains non-factual elements, including, but not limited\nto, certain statements regarding future results and other future events. These\nstatements are based on the current vision and assumptions of the management\nof the Company. They incorporate known and unknown risks and uncertainties\nthat could result in significant differences in results, profitability and\nexpected events. In addition, SMAIO, its shareholders and affiliates,\ndirectors, officers, advisors and employees have not verified the accuracy of,\nand make no representations or warranties about, the statistical information\nor forecast information contained in this press release that originates from\nor is derived from third-party sources or industry publications. Such\nstatistical data and forecast information are used in this press release for\ninformation purposes only.\n\nAPPENDIX\n\nScientific advisory board remuneration\n\nThe commitment of the members of the scientific advisory board involves\nseveral dozen hours of scientific work each year for the benefit of the\nCompany, valued at hourly rates fully in line with current market practices in\nthe United States.\n\nIn this context, and to preserve its financial resources, SMAIO has\nimplemented an original method of remunerating the surgeons, to the extent\nthat they will be remunerated mainly by the allocation of share subscription\nwarrants to their benefit.\n\nSummary of the terms and conditions of Warrants issue to Dr. Jeffrey M. Hills\n\nPursuant to the delegation of authority granted to the Board of Directors by\nthe Combined General Meeting of June 17, 2025, under the terms of the 11th\nresolution, of an extraordinary character (issue of ordinary shares and/or any\nother securities giving immediate and/or deferred access by any means to the\nCompany's capital, with cancellation of shareholders' preferential\nsubscription rights in favor of a category of persons), the Board of Directors\nmet on April 13, 2026, decided on the principle of issuing a total maximum\nnumber of 25,000 share subscription warrants (the \"Warrants\") to the benefit\nof Dr. Jeffrey M. Hills. The Board also decided to sub-delegate all powers to\nthe Chief Executive Officer to proceed with the said issue, who, by decisions\ndated May 7, 2026, determined the terms and conditions of the Warrants.\n\nThe Warrants will be issued at an amount of €4.07 per unit to be paid up in\nfull by cash payment or by offsetting against certain, liquid and payable\ndebts held by Dr. Jeffrey M. Hills against SMAIO on the date of their\nsubscription.\n\nIn addition, the Warrants will not be listed, will be issued in registered\nform and will be registered in the name of Dr. Jeffrey M. Hills in a pure\nregistered account in the Company's share accounts.\n\nIn accordance with the delegation of authority granted by the Combined General\nMeeting on June 17, 2025, and the sub-delegation of powers made to the Chief\nExecutive Officer by the Board of Directors at its meeting on April 13, 2026,\nthe subscription price of the shares allocated upon exercise of the stock\nwarrants will be at least equal to the volume-weighted average price of the\nlast five (5) trading days sessions preceding the issuance decision.\n\nThus, according to decisions made by the Director General on May 7, 2026, each\nWarrant will entitle Dr. Jeffrey M. Hills to subscribe for one (1) ordinary\nshare in the Company, subject to compliance by Dr. Jeffrey M. Hills with all\nthe legal and regulatory conditions and those set out in the plan regulations\nrelating to the Warrants, issued at a total unit price, including issue\npremium, of seven euros and seventy-eight cents (€7.78), representing a par\nvalue of 19 cents (€0.19) and seven euros and fifty-nine cents (€7.59) in\nunderwriting premium.\n\nThe maximum number of shares that may be issued on exercise of the Warrants is\ntherefore 25,000 ordinary shares, representing around 0.41% of the Company's\ncurrent capital. These shares will be registered and subject to all legal and\nstatutory provisions and will carry dividend rights as from the date of their\ncreation, it being specified that the new shares will be assimilated to the\nexisting ordinary shares. Details of the dilutive effects of this operation\nare presented below.\n\nAdditional US surgeons are expected to join SMAIO's scientific advisory board\nand should benefit from a remuneration scheme like that described above.\n\nImpact of the issue on equity per share:\n                                                                              Quote-part des capitaux propres par action (en €)    \n Prior to the Warrants issue                                                  €1.54                                                \n After exercise of the 25,000 Warrants and issue of 25,000 corresponding new  €1.58                                                \n shares                                                                                                                            \n\n\nThis impact has been calculated on the basis of the annual financial\nstatements ended December 31, 2025, indicating an equity of €9,485,535 and a\nnumber of 6,160,358 shares making up the Company’s share capital at the time\nof the issue.\n\nImpact of the issue on the situation of a shareholder:\n                                                                              Shareholder interest (in %)  \n Prior to the issue of the warrants                                           1.00%                        \n After exercise of the 25,000 Warrants and issue of 25,000 corresponding new  0.996%                       \n shares                                                                                                    \n\n\nThis impact was calculated based on the participation of a shareholder holding\n1% of the share capital prior to the issue and who did not subscribe to this\nissue.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260511764184/en/\n(https://www.businesswire.com/news/home/20260511764184/en/)\n\nSMAIO \n\nPhilippe Roussouly\n\nChairman & CEO\n\nRenaut Fritsch\n\nChief Financial Officer\n\ninvestors@smaio.com (mailto:investors@smaio.com)\n\nNewCap \n\nDusan Oresansky/Thomas Cozzolino\n\nInvestor Relations\n\nsmaio@newcap.eu \n(mailto:smaio@newcap.eu) \nT. : 01 44 71 94 92\n\nNewCap \n\nArthur Rouillé\n\nMedia Relations\n\nsmaio@newcap.eu \n(mailto:smaio@newcap.eu) \nT. : 01 44 71 00 15\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwbJF0dwa","title":"SMAIO Expands Its North American Scientific Advisory Board With a New Renowned Surgeon","author":"Business Wire","ticker":"ALSMA","created":"2026-05-11T16:40:00.174Z","tickers":["ALSMA"],"exchange":"Euronext Paris","article_body":"SMAIO Expands Its North American Scientific Advisory Board With a New Renowned\nSurgeon\n\n\n * Appointment of Dr. Jeffrey M. Hills, an orthopedic surgeon specializing in\ncomplex spinal conditions\n\n * SMAIO’s Scientific Advisory Board, now comprised of five members, is a key\nasset in the company’s expansion in the United States\n\nRegulatory News:\n\nSMAIO (Software, Machines and Adaptative Implants in Orthopaedics – Euronext\nGrowth Paris, ISIN: FR0014005I80 / Ticker: ALSMA), a French-American company\nspecialized in complex spine surgery and offering an integrated pre-, intra-\nand postoperative solution based on 3D planning software, announces the\nappointment of Dr. Jeffrey M. Hills, an orthopedic surgeon specializing in\ncomplex spinal surgery and Assistant Professor (Clinical) at UT Health San\nAntonio (Texas), to its North American Scientific Advisory Board.\n\nDr. Jeffrey M. Hills is a recognized specialist in the field of complex spinal\nconditions in adults and children. After graduating from the University of\nKansas School of Medicine, he completed his residency in orthopedic surgery at\nVanderbilt Medical Center in Nashville, Tennessee. He then completed a\nfellowship in spinal surgery at Washington University School of Medicine /\nBarnes-Jewish Hospital in St. Louis, Missouri, where he specialized in\npediatric and adult spinal deformities as well as complex reconstructive\nsurgeries.\n\nHis appointment to the SMAIO Scientific Advisory Board is part of the\ncompany’s strategy to build a network of leading experts in the United\nStates, the world’s largest market for spinal surgery. This board\ncontributes in particular to guiding technological developments, the clinical\nvalidation of solutions, and the organization of collaborative initiatives and\nexchange programs among spinal experts, such as the “Sagittal Alignment\nThink Tanks.”\n\nDr. Jeffrey M. Hills, an orthopedic surgeon, stated: “Joining SMAIO’s\nscientific advisory board represents an opportunity to contribute to the\ndevelopment of innovative solutions in spinal surgery. The integration of\nclinical data and predictive analytics tools is essential to improving patient\noutcomes. The approach developed by SMAIO, particularly through its open\nplatform, is fully in line with this trend.”\n\nPhilippe ROUSSOULY, Chairman and CEO of SMAIO, concluded: “We are very\npleased to welcome Dr. Hills to our North American Scientific Advisory Board.\nHis expertise in complex spinal surgery and his interest in data-driven\napproaches are significant assets that will support our growth in the United\nStates. This appointment underscores our commitment to surrounding ourselves\nwith the best specialists to strengthen our position in this strategic\nmarket.”\n\nDr. Jeffrey M. Hills thus becomes the fifth member of SMAIO’s North American\nScientific Advisory Board, joining Dr. Donald J. Blaskiewicz (neurosurgeon at\nSt. Luke’s Clinic in Boise, Idaho), Dr. Brian Neuman (orthopedic surgeon)\nand Dr. Camilo Molina (neurosurgeon), both practicing at Washington University\nSchool of Medicine in St. Louis, Missouri, and Dr. Tenner Guillaume\n(orthopedic surgeon at Gillette Children’s Hospital in St. Paul, Minnesota).\n\nThe terms of remuneration of Dr. Jeffrey M. Hills as a member of the\nScientific Advisory Board, mainly in the form of warrants issued to its\nbenefit, are detailed in the appendix to this press release.\n\nAbout SMAIO\n\nA precursor in the use of clinical data and imaging of the spine, SMAIO\ndesigns global solutions for spine surgery specialists. The Company has\nrecognized expertise thanks to its big data database, which has become a\nglobal reference with more than 100,000 patient cases documented. SMAIO offers\nspine surgeons a comprehensive platform, i-Kontrol, incorporating planning,\nimplantable devices and related services, enabling them to treat spinal\npathologies in a safe, effective and lasting way. The open platform deployed\nby the Company in the United States, KEOPS-4ME, is designed to offer a\npersonalized and data-driven approach for complex spine surgeries, enabling\nSMAIO to enter into commercial partnerships with major US surgical companies\nand to provide their surgeon customers with patient-specific implants. Based\nin Dallas (United States) and Lyon (France), SMAIO benefits from the skill and\nexpertise of more than 40 highly specialized employees.\n\nFor further information, please visit: www.smaio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.smaio.com&esheet=54533537&newsitemid=20260511764184&lan=en-US&anchor=www.smaio.com&index=1&md5=0e66aebbbf57f85c095f6544388c0f52)\n\nListing market: Euronext Growth Paris\n\nISIN : FR0014005I80\n\nTicker: ALSMA\n\nDisclaimer\n\nThis press release contains non-factual elements, including, but not limited\nto, certain statements regarding future results and other future events. These\nstatements are based on the current vision and assumptions of the management\nof the Company. They incorporate known and unknown risks and uncertainties\nthat could result in significant differences in results, profitability and\nexpected events. In addition, SMAIO, its shareholders and affiliates,\ndirectors, officers, advisors and employees have not verified the accuracy of,\nand make no representations or warranties about, the statistical information\nor forecast information contained in this press release that originates from\nor is derived from third-party sources or industry publications. Such\nstatistical data and forecast information are used in this press release for\ninformation purposes only.\n\nAPPENDIX\n\nScientific advisory board remuneration\n\nThe commitment of the members of the scientific advisory board involves\nseveral dozen hours of scientific work each year for the benefit of the\nCompany, valued at hourly rates fully in line with current market practices in\nthe United States.\n\nIn this context, and to preserve its financial resources, SMAIO has\nimplemented an original method of remunerating the surgeons, to the extent\nthat they will be remunerated mainly by the allocation of share subscription\nwarrants to their benefit.\n\nSummary of the terms and conditions of Warrants issue to Dr. Jeffrey M. Hills\n\nPursuant to the delegation of authority granted to the Board of Directors by\nthe Combined General Meeting of June 17, 2025, under the terms of the 11th\nresolution, of an extraordinary character (issue of ordinary shares and/or any\nother securities giving immediate and/or deferred access by any means to the\nCompany's capital, with cancellation of shareholders' preferential\nsubscription rights in favor of a category of persons), the Board of Directors\nmet on April 13, 2026, decided on the principle of issuing a total maximum\nnumber of 25,000 share subscription warrants (the \"Warrants\") to the benefit\nof Dr. Jeffrey M. Hills. The Board also decided to sub-delegate all powers to\nthe Chief Executive Officer to proceed with the said issue, who, by decisions\ndated May 7, 2026, determined the terms and conditions of the Warrants.\n\nThe Warrants will be issued at an amount of €4.07 per unit to be paid up in\nfull by cash payment or by offsetting against certain, liquid and payable\ndebts held by Dr. Jeffrey M. Hills against SMAIO on the date of their\nsubscription.\n\nIn addition, the Warrants will not be listed, will be issued in registered\nform and will be registered in the name of Dr. Jeffrey M. Hills in a pure\nregistered account in the Company's share accounts.\n\nIn accordance with the delegation of authority granted by the Combined General\nMeeting on June 17, 2025, and the sub-delegation of powers made to the Chief\nExecutive Officer by the Board of Directors at its meeting on April 13, 2026,\nthe subscription price of the shares allocated upon exercise of the stock\nwarrants will be at least equal to the volume-weighted average price of the\nlast five (5) trading days sessions preceding the issuance decision.\n\nThus, according to decisions made by the Director General on May 7, 2026, each\nWarrant will entitle Dr. Jeffrey M. Hills to subscribe for one (1) ordinary\nshare in the Company, subject to compliance by Dr. Jeffrey M. Hills with all\nthe legal and regulatory conditions and those set out in the plan regulations\nrelating to the Warrants, issued at a total unit price, including issue\npremium, of seven euros and seventy-eight cents (€7.78), representing a par\nvalue of 19 cents (€0.19) and seven euros and fifty-nine cents (€7.59) in\nunderwriting premium.\n\nThe maximum number of shares that may be issued on exercise of the Warrants is\ntherefore 25,000 ordinary shares, representing around 0.41% of the Company's\ncurrent capital. These shares will be registered and subject to all legal and\nstatutory provisions and will carry dividend rights as from the date of their\ncreation, it being specified that the new shares will be assimilated to the\nexisting ordinary shares. Details of the dilutive effects of this operation\nare presented below.\n\nAdditional US surgeons are expected to join SMAIO's scientific advisory board\nand should benefit from a remuneration scheme like that described above.\n\nImpact of the issue on equity per share:\n                                                                              Quote-part des capitaux propres par action (en €)    \n Prior to the Warrants issue                                                  €1.54                                                \n After exercise of the 25,000 Warrants and issue of 25,000 corresponding new  €1.58                                                \n shares                                                                                                                            \n\n\nThis impact has been calculated on the basis of the annual financial\nstatements ended December 31, 2025, indicating an equity of €9,485,535 and a\nnumber of 6,160,358 shares making up the Company’s share capital at the time\nof the issue.\n\nImpact of the issue on the situation of a shareholder:\n                                                                              Shareholder interest (in %)  \n Prior to the issue of the warrants                                           1.00%                        \n After exercise of the 25,000 Warrants and issue of 25,000 corresponding new  0.996%                       \n shares                                                                                                    \n\n\nThis impact was calculated based on the participation of a shareholder holding\n1% of the share capital prior to the issue and who did not subscribe to this\nissue.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260511764184/en/\n(https://www.businesswire.com/news/home/20260511764184/en/)\n\nSMAIO \n\nPhilippe Roussouly\n\nChairman & CEO\n\nRenaut Fritsch\n\nChief Financial Officer\n\ninvestors@smaio.com (mailto:investors@smaio.com)\n\nNewCap \n\nDusan Oresansky/Thomas Cozzolino\n\nInvestor Relations\n\nsmaio@newcap.eu \n(mailto:smaio@newcap.eu) \nT. : 01 44 71 94 92\n\nNewCap \n\nArthur Rouillé\n\nMedia Relations\n\nsmaio@newcap.eu \n(mailto:smaio@newcap.eu) \nT. : 01 44 71 00 15\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-11T16:40:00.219433189Z","server_sent_at_ms":1778517600219},"received_at":"2026-05-11T16:40:00.274Z","source_url":"https://www.businesswire.com/news/home/20260511764184/en/"},"analysis":null,"durationMs":null,"modelName":null}}